EN DE
Watch Monopar Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Monopar Therapeutics Inc (MNPR) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Monopar Therapeutics Inc stock $17.43, price $70.32, upside -75.2%, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MT Monopar Therapeutics Inc logo Thin data Nov 1, 2026

Monopar Therapeutics Inc

MNPR · US
Solid, but very expensive

Our calculation puts a fair price 75% below what the stock costs today.

Quality 51/100
Mixed vs. peers (4/7)
Fair value $17.43 · Strongly overvalued (−75.2%)
Weak Growth
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
⚠ Dilution
Watch Monopar Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$123.84 $1.45 Fair Value $17.43 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.

How to read this chart

60‑month range $1.45 – $123.84 · fair‑value band $11.50 – $21.78 · the $70.32 price screens above the $17.43 fair value. As of Nov 1, 2026.

Follow Monopar Therapeutics in your weekly email

Every Wednesday you see whether Monopar Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

Show moreShow less

The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease.

The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Stock analysis

Monopar Therapeutics Inc (MNPR) currently trades at $70.32, while our model-based Fair Value estimate is $17.43, 75.2% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $11.50 (bear) to $21.78 (bull), the price of $70.32 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Monopar Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$13.7M in FY2025.

Key figures

Market cap $601M Small · EPS (TTM) $−2.20 · Return on equity −19.5% · Return on assets (EBIT) −56.6% · Free cash flow −$12.2M · Net cash $61.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 40% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −75%, MNPR screens richer than that median.

Fair Value models

Bear $11.50 Fair Value $17.43 Bull $21.78
Price $70.32 · Upside -75.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $13.53 $20.50 $25.62 52
All 1 models by family
Asset-Based
NCAV (Graham) $13.53 $20.50 $25.62 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 51/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 63
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 11
How calm the share price moves, does not count
Price momentum 36
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 21
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MNPR screens overvalued: fair value 75% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Monopar Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 51 · Above median
Fair Value upside −75.2% · Bottom 25%
Profitability
Return on assets −9.8% · Above median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.36× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $927.89 $1,275 +37% vs MNPR
WuXi Biologics (Cayman) Inc 2269 HK$44.48 HK$49.57 +11% vs MNPR
Vertex Pharmaceuticals Incorporated VRTX $558.88 $614.77 +10% vs MNPR
Samsung Biologics Co 207940 1,487,000 KRW 1,635,700 KRW +10% vs MNPR
Genmab A/S GMAB kr 3,912 kr 4,303 +10% vs MNPR
argenx SE ARGX $892.87 $908.40 +2% vs MNPR
CSL Limited CSL A$201.16 A$178.62 −11% vs MNPR
BeOne Medicines AG ONC $370.33 $254.12 −31% vs MNPR
Celltrion, Inc 068270 191,600 KRW 74,945 KRW −61% vs MNPR
Royalty Pharma plc RPRX $67.18 $19.01 −72% vs MNPR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Monopar Therapeutics Inc · Fair Value
$17.43 −75%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Monopar Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/MNPR

Frequently asked questions

Is Monopar Therapeutics Inc (MNPR) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of $17.43 versus a price of $70.32, about −75% upside (overvalued).
What is the fair value of MNPR?
Our model-based fair value for Monopar Therapeutics Inc is $17.43 (as of Nov 1, 2026), built from audited fundamentals. The current price: $70.32.
What is the quality score of MNPR?
Monopar Therapeutics Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Monopar Therapeutics Inc (MNPR)?
Our model-based price target is the fair value of $17.43 (as of Nov 1, 2026) from 1 valuation models. Cautious scenario $11.50, optimistic scenario $21.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Monopar Therapeutics Inc stock forecast for 2026?
Our models put fair value at $17.43, about −75% upside versus a price of $70.32 (overvalued). Cautious scenario $11.50, optimistic scenario $21.78. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Monopar Therapeutics Inc (MNPR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Monopar Therapeutics Inc it is $17.43 per share (as of Nov 1, 2026), against a price of $70.32. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Monopar Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 1, 2026, MNPR trades above its calculated fair value: price $70.32, fair value $17.43, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MNPR?
No. The price is what the market pays today ($70.32); the fair value is what the company's own numbers justify ($17.43). For Monopar Therapeutics Inc the two are $52.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is Monopar Therapeutics Inc worth?
The market values Monopar Therapeutics Inc at about $601M (market capitalisation, as of Nov 1, 2026). Per share that is $70.32; our models calculate a fair value of $17.43 per share.
What do the bullish and bearish scenarios say about MNPR?
Our models span a range for Monopar Therapeutics Inc: cautious scenario $11.50, base $17.43, optimistic $21.78 per share (as of Nov 1, 2026, price $70.32). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Monopar Therapeutics Inc (MNPR)?
Balance-sheet figures for Monopar Therapeutics Inc (as of Nov 1, 2026): return on equity −19.5%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is MNPR from its 52-week high?
Monopar Therapeutics Inc trades at $70.32, about 43% below its 52-week high of $123.84 and 40% above the low of $50.12 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $17.43 is for.
Which stocks are comparable to Monopar Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Monopar Therapeutics Inc stock attractive at the current price?
The data as of Nov 1, 2026: price $70.32, calculated fair value $17.43 (−75%), Quality Score 51/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MNPR calculated?
We run Monopar Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $17.43, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Monopar Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Monopar Therapeutics Inc (MNPR)?
The closing price on Oct 30, 2026 was $70.32. Our model-based fair value is $17.43, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Monopar Therapeutics Inc right now?
The price sits above even our optimistic bull case ($21.78). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($11.50 to $21.78) leaves room in how you read the outcome.

Key figures of Monopar Therapeutics Inc

How large is the market capitalisation of Monopar Therapeutics Inc (MNPR)?
The market capitalisation of Monopar Therapeutics Inc is $601M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Monopar Therapeutics Inc (MNPR)?
Earnings per share at Monopar Therapeutics Inc are $−2.20. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Monopar Therapeutics Inc (MNPR)?
The return on equity (ROE) of Monopar Therapeutics Inc is −19.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Monopar Therapeutics Inc (MNPR)?
On an EBIT basis the return on assets of Monopar Therapeutics Inc is −56.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Monopar Therapeutics Inc (MNPR) generate?
The free cash flow of Monopar Therapeutics Inc is −$12.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Monopar Therapeutics Inc (MNPR) hold?
Monopar Therapeutics Inc holds more cash than debt, $61.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Monopar Therapeutics Inc in the live analysis

One click puts Monopar Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.